Clinical Trial Update: Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant cadonilimab with cisplatin and nab-paclitaxel for resectable head and neck squamous cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Cadonilimab
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Xuekui Liu | Conditions: Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable | Phase 2 | Status: UNKNOWN